# Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

> **NCT03843632** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 150 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** VARIVAX™

## Key facts

- **NCT ID:** NCT03843632
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2020-06-19
- **Final completion:** 2020-06-19
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843632, "Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03843632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*